4D Molecular Therapeutics, Inc. (FDMT) Cash and securities
- Total cash · latest quarter (USD): Value $361.33M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $361.33M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $70.37M + $290.96M ≈ $361.33M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 70.37M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 290.96M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Cash and current securities | 361.33M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $361.33M | (m) | $70.37M | $290.96M | (m) |
| 2026-03-31 | $390.89M | (m) | $72.49M | $318.40M | (m) |
| 2025-12-31 | $402.65M | (m) | $60.24M | $342.41M | (m) |
| 2025-09-30 | $305.06M | (m) | $48.55M | $256.51M | (m) |
| 2025-06-30 | $293.23M | (m) | $77.16M | $216.07M | (m) |
| 2025-03-31 | $321.44M | (m) | $133.53M | $187.91M | (m) |
| 2024-12-31 | $424.88M | (m) | $149.34M | $275.54M | (m) |
| 2024-09-30 | $501.89M | (m) | $187.54M | $314.35M | (m) |
| 2024-06-30 | $541.95M | (m) | $189.06M | $352.88M | (m) |
| 2024-03-31 | $525.91M | (m) | $275.59M | $250.32M | (m) |
| 2023-12-31 | $288.23M | (m) | $249.11M | $39.12M | (m) |
| 2023-09-30 | $319.66M | (m) | $275.68M | $43.99M | (m) |
| 2023-06-30 | $310.34M | (m) | $236.31M | $74.03M | (m) |
| 2023-03-31 | $200.45M | (m) | $78.57M | $121.89M | (m) |
| 2022-12-31 | $213.55M | (m) | $52.35M | $161.20M | (m) |
| 2022-09-30 | $227.72M | (m) | $108.30M | $119.42M | (m) |
| 2022-06-30 | $241.09M | (m) | $113.48M | $127.60M | (m) |
| 2022-03-31 | $236.15M | (m) | $75.97M | $160.18M | (m) |
| 2021-12-31 | $247.78M | (m) | $153.00M | $94.78M | (m) |
| 2021-09-30 | $161.68M | (m) | $90.99M | $70.69M | (m) |
| 2021-06-30 | (m) | (m) | $243.74M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $259.87M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $276.73M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $49.65M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |